PierreHenri Benhamou - DBV Technologies Chairman of the Board, CEO
| DBV Stock | EUR 1.62 0.09 1.63% |
Chairman
Dr. PierreHenri Benhamou was appointed NonExecutive Chairman of DBV Technologies as of November 16, 2018. He was Chairman of the Board and Chief Executive Officer of the Company from November 1, 2015. Previouslym he was Chief Scientific Officer of DBV Technologies SA from January 17, 2012. He served also as Chairman of the Board, Chief Executive Officer, Chief Scientific Officer between February 25, 2010 and December 23, 2010. He is the cofounder of the Company. He was first appointed on the Companys Board of Directors on December 23, 2005. He is a former Interne des Hopitaux and former Chief of Clinic. He is specialized in pediatric gastroenterology and has held a number of senior clinical positions after studying Pediatrics in Paris and Amiens. In 1989, Dr. Benhamou created the Centre for Digestive Exploration of Infants at the Surgical Clinic in BoulogneBillancourt. Dr. Benhamou received the Prize for Innovation from the Altran Foundation in 2003 for his work on the development of patch tests for the diagnosis of cows milk proteins allergy. since 2018.
| Tenure | 6 years |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 2.48 M in total debt with debt to equity ratio (D/E) of 2.0, which is about average as compared to similar companies. DBV Technologies has a current ratio of 3.27, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DBV Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, DBV Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DBV Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DBV to invest in growth at high rates of return. When we think about DBV Technologies' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Harald Schrimpf | PSI Software AG | 59 | |
Management Performance
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Ehouarn, Industrial Development and Production Director | ||
| Claude Thebault, Medical Director | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Laurent Martin, Director of Regulatory Affairs | ||
| Viviane Monges, Director | ||
| Caroline Daniere, Chief Staff | ||
| Didier Hoch, Director | ||
| Daniel Tass, CEO Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Pascal Wotling, Chief Officer | ||
| Charles Ruban, Chief Development Officer | ||
| Nathalie Donne, Director of Corporate Communication & Business Development | ||
| Lucie Mondoulet, Director of Research | ||
| Anne Pollak, Head Relations | ||
| Chahra Louafi, Director - Representative of CDC Entreprises (Innobio) | ||
| Peter Hutt, Independent Director | ||
| Michele Robertson, Chief Officer | ||
| Rafaele Tordjman, Director - Representative of Sofinnova Partners | ||
| Bertrand Dupont, Chief Technical Officer | ||
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Veronique Foutel, Chief Strategic Marketing Officer | ||
| Daniel Tasse, CEO | ||
| Rafale Tordjman, Director - Representative of Sofinnova Partners | ||
| Joan Schmidt, Executive Vice President General Counsel | ||
| George Horner, Director | ||
| Torbjorn Bjerke, Independent Director | ||
| Pharis Mohideen, Chief Medical Officer | ||
| PierreHenri Benhamou, Chairman of the Board, CEO | ||
| Torbjrn Bjerke, Independent Director | ||
| Mailys Ferrere, Director | ||
| Michel Rosen, Director | ||
| David Schilansky, CFO |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.04) % | |||
| Current Valuation | 51.36 M | |||
| Shares Outstanding | 93.97 M | |||
| Shares Owned By Insiders | 6.50 % | |||
| Shares Owned By Institutions | 33.06 % | |||
| Price To Earning | (14.30) X | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 28.05 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards DBV Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, DBV Technologies' short interest history, or implied volatility extrapolated from DBV Technologies options trading.
Pair Trading with DBV Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.Moving together with DBV Stock
| 0.67 | CSJA | CSL LTD SPONADR | PairCorr |
| 0.67 | CSJ | CSL Limited | PairCorr |
Moving against DBV Stock
| 0.76 | MBG | Mercedes Benz Group | PairCorr |
| 0.65 | DBPE | Xtrackers LevDAX | PairCorr |
| 0.61 | NOVA | Novo Nordisk AS | PairCorr |
| 0.59 | SSUN | Samsung Electronics | PairCorr |
| 0.57 | SSUN | Samsung Electronics | PairCorr |
The ability to find closely correlated positions to DBV Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DBV Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DBV Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DBV Technologies SA to buy it.
The correlation of DBV Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DBV Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DBV Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DBV Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DBV Technologies SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in DBV Stock please use our How to Invest in DBV Technologies guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for DBV Stock analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |